WO2003033658A3 - Neutrokine-alpha et variant d'epissage de neutrokine-alpha - Google Patents
Neutrokine-alpha et variant d'epissage de neutrokine-alpha Download PDFInfo
- Publication number
- WO2003033658A3 WO2003033658A3 PCT/US2002/032910 US0232910W WO03033658A3 WO 2003033658 A3 WO2003033658 A3 WO 2003033658A3 US 0232910 W US0232910 W US 0232910W WO 03033658 A3 WO03033658 A3 WO 03033658A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- neutrokine
- alpha
- methods
- alphasv
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002476675A CA2476675A1 (fr) | 2001-10-17 | 2002-10-16 | Neutrokine-alpha et variant d'epissage de neutrokine-alpha |
EP02786413A EP1507793A4 (fr) | 2001-10-17 | 2002-10-16 | Neutrokine-alpha et variant d'epissage de neutrokine-alpha |
AU2002351495A AU2002351495A1 (en) | 2001-10-17 | 2002-10-16 | Neutrokine-alpha and neutrokine-alpha splice variant |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32950801P | 2001-10-17 | 2001-10-17 | |
US60/329,508 | 2001-10-17 | ||
US32974701P | 2001-10-18 | 2001-10-18 | |
US60/329,747 | 2001-10-18 | ||
US33083501P | 2001-10-31 | 2001-10-31 | |
US60/330,835 | 2001-10-31 | ||
US33147801P | 2001-11-16 | 2001-11-16 | |
US60/331,478 | 2001-11-16 | ||
US33672601P | 2001-12-07 | 2001-12-07 | |
US60/336,726 | 2001-12-07 | ||
US36854802P | 2002-04-01 | 2002-04-01 | |
US60/368,548 | 2002-04-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003033658A2 WO2003033658A2 (fr) | 2003-04-24 |
WO2003033658A3 true WO2003033658A3 (fr) | 2004-05-27 |
Family
ID=27559746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/032910 WO2003033658A2 (fr) | 2001-10-17 | 2002-10-16 | Neutrokine-alpha et variant d'epissage de neutrokine-alpha |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1507793A4 (fr) |
AU (1) | AU2002351495A1 (fr) |
CA (1) | CA2476675A1 (fr) |
WO (1) | WO2003033658A2 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
CA2407910C (fr) | 2000-06-16 | 2013-03-12 | Steven M. Ruben | Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
US20030091565A1 (en) | 2000-08-18 | 2003-05-15 | Beltzer James P. | Binding polypeptides and methods based thereon |
CA2583900A1 (fr) | 2004-10-13 | 2006-04-27 | The Washington University | Utilisation de baff dans le traitement du sepsis |
EP3037544A1 (fr) | 2005-10-13 | 2016-06-29 | Human Genome Sciences, Inc. | Procedes et compositions destinees au traitement de patients atteints de lupus erythematosus systémique positifs pour des auto-anticorps |
US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
AU2006318539B2 (en) | 2005-11-23 | 2012-09-13 | Genentech, Inc. | Methods and compositions related to B cell assays |
WO2007123765A2 (fr) | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | NEUTROKINE-ALPHA et variant d'epissage de la neutrokine-alpha |
CN103030696B (zh) | 2006-05-30 | 2016-09-28 | 健泰科生物技术公司 | 抗体和免疫偶联物及其用途 |
KR20150008503A (ko) | 2007-10-30 | 2015-01-22 | 제넨테크, 인크. | 양이온 교환 크로마토그래피에 의한 항체 정제 |
US10927144B2 (en) | 2008-08-14 | 2021-02-23 | Genentech, Inc. | Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography |
CA2734275A1 (fr) | 2008-09-10 | 2010-03-18 | Genentech, Inc. | Compositions et procedes permettant d'eviter la degradation oxydative des proteines |
BR112012021873B8 (pt) | 2010-03-22 | 2021-09-14 | Genentech Inc | composição de matéria, artigo de manufatura, métodos para preparar uma composição, para aumentar a estabilidade de uma proteína em solução aquosa livre de polissorbato e para prevenir ou reduzir a agregação de uma proteína em solução aquosa livre de polissorbato |
BR112012027828A2 (pt) | 2010-05-03 | 2016-08-09 | Genentech Inc | composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína |
KR101924653B1 (ko) | 2010-06-24 | 2018-12-03 | 제넨테크, 인크. | 단백질-함유 제제를 안정화시키기 위한 알킬글리코시드 함유 조성물 및 방법 |
CN104125963B (zh) | 2011-12-22 | 2018-08-17 | 弗·哈夫曼-拉罗切有限公司 | 使用离子交换膜层析改进下游蛋白质纯化步骤的方法 |
MX2021012032A (es) | 2019-04-01 | 2021-11-03 | Genentech Inc | Composiciones y metodos para estabilizar formulaciones que contienen proteinas. |
CN110176272B (zh) * | 2019-04-18 | 2021-05-18 | 浙江工业大学 | 一种基于多序列联配信息的蛋白质二硫键预测方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9612752A (pt) * | 1996-10-25 | 2000-01-18 | Human Genome Sciences Inc | Neutrocina |
AU2001288260A1 (en) * | 2000-08-15 | 2002-03-13 | Human Genome Sciences, Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
-
2002
- 2002-10-16 EP EP02786413A patent/EP1507793A4/fr not_active Withdrawn
- 2002-10-16 AU AU2002351495A patent/AU2002351495A1/en not_active Abandoned
- 2002-10-16 CA CA002476675A patent/CA2476675A1/fr not_active Abandoned
- 2002-10-16 WO PCT/US2002/032910 patent/WO2003033658A2/fr active Search and Examination
Non-Patent Citations (6)
Title |
---|
MACKAY ET AL.: "Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations", J. EXP. MED., vol. 190, no. 11, 6 December 1999 (1999-12-06), pages 1697 - 1710, XP000915435 * |
MOORE ET AL.: "BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator", SCIENCE, vol. 285, 9 July 1999 (1999-07-09), pages 260 - 263, XP002142252 * |
NARDELLI ET AL.: "B lymphocyte stimulator (BLyS): A therapeutic trichotomy for the treatment of B lymphocyte diseases", LEUKEMIA AND LYMPHOMA, vol. 43, no. 7, 2002, pages 1367 - 1373, XP002973536 * |
SCHNEIDER ET AL.: "BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth", J. EXP. MED., vol. 189, no. 11, 17 June 1999 (1999-06-17), pages 1747 - 1756, XP000915409 * |
See also references of EP1507793A4 * |
WARE ET AL.: "APRIL and BAFF connect autoimmunity and cancer", J. EXP. MEDICINE, vol. 192, no. 11, 2000, pages F35 - F37, XP002224635 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002351495A1 (en) | 2003-04-28 |
WO2003033658A2 (fr) | 2003-04-24 |
EP1507793A4 (fr) | 2006-02-01 |
CA2476675A1 (fr) | 2003-04-24 |
EP1507793A2 (fr) | 2005-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002018620A3 (fr) | Neutrokine-alpha et variant d'epissage de neutrokine-alpha | |
WO2003033658A3 (fr) | Neutrokine-alpha et variant d'epissage de neutrokine-alpha | |
WO2007123765A3 (fr) | NEUTROKINE-ALPHA et variant d'epissage de la neutrokine-alpha | |
WO2002008284A3 (fr) | Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese | |
WO2002000690A3 (fr) | Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese | |
WO2001055367A8 (fr) | Acides nucleiques, proteines et antigenes | |
WO2005056600A3 (fr) | Anticorps monoclonaux se liant ou neutralisant le virus de la dengue | |
WO2001055317A8 (fr) | Acides nucleiques, proteines et anticorps | |
WO2000053753A3 (fr) | Activation ou inhibition de l'angiogenese et de la cardiovascularisation | |
CY1109518T1 (el) | Αναστολεας ενεργοποιητη αυξητικου παραγοντα ηπατοκυτταρων για χρηση σε διαμορφωση αγγειογενεσης και καρδιοαγγειωσης | |
WO2000053757A3 (fr) | Activation et inhibition de l'angiogenese et de la cardiovascularisation | |
WO2000053752A3 (fr) | Activation ou inhibition de l'angiogenese et de la cardiovascularisation | |
WO2001025433A3 (fr) | Nouveaux polypeptides, leurs acides nucleiques et leurs procedes d'utilisation dans l'angiogenese et la vascularisation | |
WO2001040464A8 (fr) | Kinase 3 associee au recepteur de l'interleukine 1 (irak3) et son utilisation pour stimuler ou inhiber l'angiogenese et la cardiovascularisation | |
AU5441200A (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
WO2004020591A3 (fr) | Methodes d'utilisation de nouveaux polypeptides humains codes par des polynucleotides | |
WO2002044366A3 (fr) | Nouvelles proteines humaines specifiques de la retine c7orf9, c12orf7, mpp4 et f379 | |
WO2001055300A8 (fr) | Acides nucleiques, proteines et anticorps | |
WO2001000662A3 (fr) | Utilisation de polypeptides fgh-8 humains comme agents neurotrophiques | |
WO2004039952A3 (fr) | Procedes d'utilisation de polypeptides humains codes par des polynucleotides | |
WO2004046310A3 (fr) | Nouveaux polypeptides de souris codes par des polynucleotides et leurs procedes d'utilisation | |
WO2001055313A3 (fr) | Acides nucleiques, proteines et anticorps |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2476675 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002786413 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002786413 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002786413 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |